Crucell N.V.

Published Date: 06/06/2011
Category: Therapies & Markets

Research Report Decription

Crucell N.V. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Crucell N.V. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Crucell N.V. in the form of a SWOT analysis
• An in-depth view of the business model of Crucell N.V. including a breakdown and examination of key business segments Intelligence on Crucell N.V.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Crucell N.V., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Crucell N.V. and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions 
• Assess Crucell N.V. as a prospective partners, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Crucell N.V.’s business structure, strategy and prospects

Companies Mentioned:

Crucell N.V.

Paper Highlights:

Crucell is a biopharmaceutical company engaged in discovering, developing and commercializing vaccines and antibodies against infectious diseases. The company's product portfolio is focused on three distinct areas: paediatric, travel and endemic, and respiratory. The company primarily operates in Europe, North America and Asia. It is headquartered in Leiden, the Netherlands and employed 1,248 people as of December 2009. The company recorded revenues of E338.2 million (approximately $471.6 million) during the financial year (FY) ended December 2009, an increase of 26.6% over FY2008. The increase in revenues was due to strong sales of paediatric and respiratory vaccines. The operating profit of the company was E39 million (approximately $54.4 million) during FY2009, as compared of the operating profit of E7.4 million (approximately $10.4 million) in FY2008. The net profit of the company was E23.9 million (approximately $33.4 million) in FY2009, an increase of 68% over FY2008.